Dermatology

Psoriatic arthritis

Questions discussed in this category

How do you approach managing nausea and GI side effects when initiating methotrexate?

2 Answers available

How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics?

1 Answer available

Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?

2 Answers available

Would you consider using a JAK inhibitor in combination with an IL 23 inhibitor in cases of severe psoriasis, psoriatic arthritis, or axial spondyloarthritis that is refractory to multiple biologic DMARDs?

2 Answers available

What is your approach to using apremilast for psoriatic arthritis in patients with history of depression?

1 Answer available

Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?

1 Answer available

Papers discussed in this category

The Journal of rheumatology, 2012-01

Combination biologic treatment of refractory psoriasis and psoriatic arthritis.

JAAD Case Rep, 2019 Oct 10

Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis.

Clinical rheumatology, 1988 Sep

Treatment of psoriatic arthritis with sulphasalazine: a one year open study.

Journal of the American Academy of Dermatology, 1987 Apr

Gold therapy and its indications in dermatology. A review.

Journal of the American Academy of Dermatology, 2020 May 19

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.

Annals of the rheumatic diseases, 2018-09

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Arthritis & rheumatology (Hoboken, N.J.), 2019-02

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.

RMD open, 2020 Feb

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.

Trials, 2022 Sep 05

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.

Related Topics in Dermatology